A molecular risk score based on 4 functional pathways for advanced classical Hodgkin lymphoma

Area of Science:

• Oncology
• Molecular Biology
• Biomarker Discovery

Background:

• Advanced classical Hodgkin lymphoma has a significant relapse rate despite treatment improvements.
• Current predictive systems lack accuracy in identifying high-risk patients.
• Novel biomarkers are needed for precise risk stratification.

Purpose of the Study:

• To develop a quantitative reverse-transcription polymerase chain reaction (RT-PCR) assay for risk prediction in classical Hodgkin lymphoma.
• To integrate gene expression from tumor cells and their microenvironment into a predictive model.
• To identify patients with a high risk of treatment failure.

Main Methods:

• A multistep approach was used to design a quantitative RT-PCR assay.
• Thirty genes were evaluated in 282 formalin-fixed paraffin-embedded samples.
• An 11-gene model was developed to create a molecular risk score.

Main Results:

• The 11-gene model identified distinct low- and high-risk groups with significantly different 5-year failure-free survival rates (74% vs. 44.1% in the estimation set; 67.5% vs. 45.0% in the validation set).
• The model incorporates cell cycle, apoptosis, macrophage activation, and interferon regulatory factor 4 pathways.
• A combined model with stage IV identified a very high-risk group with a 25.2% 5-year failure-free survival.

Conclusions:

• The developed molecular risk score is a promising tool for predicting treatment failure in classical Hodgkin lymphoma.
• This assay can be applied to routine formalin-fixed paraffin-embedded samples.
• The model enhances risk stratification, potentially guiding treatment decisions for high-risk patients.